• Consolidated revenue stood at ₹5,566.9 crore, up approximately 28.9% year-on-year.
• Standalone revenue rose to ₹4,052.5 crore, showing a growth of 17.6% year-on-year.
• Strong sales volume growth was a key driver, supported by both domestic demand and global expansion.
2. Volume Performance:
• Total sales volume reached 312.4 million cases, an increase of 30.1% compared to the same quarter last year.
• Organic volume growth in India was approximately 15.5%.
• The remaining growth came from acquisitions and international operations in South Africa and the Democratic Republic of Congo (DRC).
3. Profitability and Margins:
• EBITDA came in at ₹1,263.96 crore, growing 27.8% year-on-year.
• EBITDA margin declined slightly by about 20 basis points due to integration of lower-margin international businesses.
• Net profit (PAT) increased by 33.5% to ₹731.36 crore.
• Net profit margin was approximately 13.05%, nearly stable compared to the previous year.
4. EPS and Analyst Estimates:
• Earnings Per Share (EPS) was reported at ₹2.15.
• EPS missed average analyst expectations by a narrow margin (estimated around ₹2.16).
• Despite the slight miss, the earnings trend remains healthy and consistent.
5. Gross Margin and Cost Trends:
• Gross margin for the quarter stood at 54.6%, down by around 171 basis points.
• Decline was mainly due to a shift in product and geographical mix after the consolidation of South African and DRC operations.
6. Depreciation and Finance Cost:
• Depreciation expenses rose by 45%, attributed to the commissioning of three new plants at Supa, Gorakhpur, and Khordha.
• Finance costs remain low in India post-debt repayment, with minor interest costs from international leases.
• Interest income during the quarter was ₹10.8 crore, offsetting some of the borrowing costs.